CHAF1B:在肝细胞癌中,索拉费尼布耐药性背后的隐藏罪祸首
Wenfeng Zhuo1, Jiali Zhao1, Zhouying Zheng1
1Department of Hepatobiliary Surgery, the Fifth Affiliated Hospital, Sun Yat-sen University 519000 Zhuhai, Guangdong, China.
International journal of medical sciences
|October 6, 2025
概括
染色体组合因子1B (CHAF1B) 通过激活PI3K/Akt/HIF-1α通路,驱动肝细胞癌 (HCC) 中的索拉芬尼抗性. 用索拉费尼布向CHAF1B为HCC患者提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 肝细胞癌 (HCC) 是一个主要的全球健康问题,治疗选择有限.
- 索拉费尼布是高级HCC的标准疗法,但耐药性仍然是一个重大挑战.
- 染色体组合因子1B (CHAF1B) 在HCC中索拉芬尼抗性的作用尚不清楚.
研究的目的:
- 调查CHAF1B在HCC中索拉芬尼抗性的作用.
- 阐明CHAF1B介导的索拉芬尼布耐药性的潜在分子机制.
- 探索向CHAF1B的治疗潜力与HCC治疗中的索拉芬尼结合使用.
主要方法:
- 生物信息学分析,免疫组织化学和西部斑点来评估CHAF1B表达.
- 细胞增殖,殖民地形成,迁移,入侵和流动细胞计测试以评估HCC细胞行为.
- RNA测序和特定途径的抑制剂,以确定CHAF1B的作用机制.
主要成果:
- 在HCC组织和抗索拉芬尼布细胞中,CHAF1B的升高调节,与患者的存活率差相关.
- 高CHAF1B表达促进HCC的扩散,迁移,入侵和索拉芬尼布耐药性.
- CHAF1B激活PI3K/Akt/HIF-1α通路,从而导致对索拉芬尼布的耐药性.
结论:
- CHAF1B是HCC中索拉芬尼抗性的关键调节者.
- 向CHAF1B,与索拉芬尼结合,可以克服化学抵抗.
- 调节PI3K/Akt/HIF-1α信号轴是HCC的潜在治疗策略.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.9K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Retinoblastoma Gene
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.7K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
